Did You Know? The Neuroendocrine Unit at the EVMS Strelitz Diabetes Center is a worldwide referral center for patients with neuroendocrine tumors (NETS), and is one of the few centers offering unique expertise for evaluating these tumors and specialized care for NETS patients.
The Neuroendocrine Unit at the EVMS Strelitz Diabetes Center, directed by Dr. Aaron Vinik, MD, PhD, serves a global authority on autonomic and somatic neuropathy. Diabetic neuropathy (DN) is the leading cause of foot ulcers and amputations in diabetics patients, with an estimated rate of >60,000 non-traumatic amputations per year (CDC). DN is also the leading cause of falls in the elderly.
It is the leading research unit in exploring the pathology and treatments for diabetic neuropathy. It was the first to use immune therapy as a treatment for DN. However, the Unit is not limited to diabetic patients, but also follows those with autoimmune neuropathy. Using novel biological markers and diagnostic evaluations, in conjunction with standard clinical and laboratory diagnostics, the Unit continues to improve and lead in the management of neuropathy.
The Neuroendocrine Unit also serves as a coordinating center for many new therapeutic trials, providing sophisticated diagnostics and partnerships with superb laboratory support.